SCHEMBL14729153

SCHEMBL14729153

Cc1ccc(OC(=O)N2CCC(Oc3nc4ccc(C5CCN(S(=O)(=O)CCCCO)CC5)cc4s3)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
FAAH O00519 1/20 0.36
NAMPT P43490 2/20 0.35
PDE4B Q07343 1/20 0.35
LMNA P02545 2/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 1/20 0.34
GPR119 Q8TDV5 2/20 0.34
ACACB O00763 2/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728960 0.93 FAAH (0.38) FAAHNAMPTPDE4BLMNATP53
SCHEMBL14729154 0.89 TLR9 (0.38) TLR9TLR8TLR7FAAHNAMPT
SCHEMBL14729023 0.84 GPR119 (0.34) TLR9TLR8TLR7NAMPTPDE4B
SCHEMBL14728958 0.82 FAAH (0.38) FAAHPDE4BLMNATP53MAPT
SCHEMBL14729022 0.82 GPR119 (0.36) TLR9TLR8TLR7NAMPTPDE4B
SCHEMBL14729126 0.82 GPR119 (0.41) TLR8TLR7NAMPTMAPTGPR119
SCHEMBL14728924 0.80 DRD2 (0.42) LMNASMN1; SMN2CYP1A2CYP2C9
SCHEMBL16015963 0.77 FAAH (0.37) FAAHNAMPTPDE4BLMNATP53
SCHEMBL2590794 0.76 GPR119 (0.39) MAPTGPR119NPC1
SCHEMBL14729187 0.76 GPR119 (0.35) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR4 TLR9 315/4885TLR8 1063/4885TLR7 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.